Clinical Trial

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-29.
Status change: Not Yet Recruiting → Recruiting 2026-02-08
Trial Details
NCT Number NCT07104812
Lead Sponsor Mayo Clinic
Collaborators: RECORDATI GROUP
Conditions Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Enrollment 15 participants
Start Date 2026-01-14
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-11